HomeBUSINESS
BUSINESS

Ono Grabs Rights to 2 XPO1 Inhibitors in Japan, Asia
(Oct.13.2017)

Ono Pharmaceutical said on October 12 that it has gained exclusive development and commercialization rights in Japan and some Asian markets for two XPO1 inhibitors being developed by US pharma company Karyopharm Therapeutics. The deal covers all cancer types ...
(LOG IN FOR FULL STORY)

News Calendar